Log In
Print
BCIQ
Print
Print this Print this
 

BCX4161

  Manage Alerts
Collapse Summary General Information
Company BioCryst Pharmaceuticals Inc.
DescriptionSelective inhibitor of plasma kallikrein that subsequently suppresses bradykinin production
Molecular Target Kallikrein
Mechanism of ActionKallikrein inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationAngioedema
Indication DetailsTreat hereditary angioedema (HAE)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today